TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has entered into a pharmaceutical manufacturing…

Source

Previous articleAlgernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property
Next articlePT287 – Josh Hardman – Psychedelic Stocks, Data Privacy, and Drug Development